A special scan that tracks sugar use in artery walls can reliably show whether inflammation is going down — and it works in different parts of the body’s arteries.
Scientific Claim
The 18F-FDG PET-CT technique is a feasible noninvasive method for quantifying arterial wall inflammation in humans, as demonstrated by consistent TBR reductions following statin therapy across multiple vascular beds including the aorta, carotid, and femoral arteries.
Original Statement
“18F-FDG PET-CT is considered to be a good indicator of arterial wall inflammation... This meta-analysis clearly showed a decrease of arterial wall inflammation after treatment with statins based on a significant reduction of arterial wall 18F-FDG uptake according to TBR index using 18F-FDG PET-CT.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study does not claim 18F-FDG PET-CT is a perfect or validated diagnostic tool, but rather that it is 'considered a good indicator' and showed consistent results. The language is appropriately cautious and descriptive.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bValidation of 18F-FDG PET-CT TBR as a surrogate endpoint for arterial inflammation by correlating it with histological inflammation in human arterial tissue.
Validation of 18F-FDG PET-CT TBR as a surrogate endpoint for arterial inflammation by correlating it with histological inflammation in human arterial tissue.
What This Would Prove
Validation of 18F-FDG PET-CT TBR as a surrogate endpoint for arterial inflammation by correlating it with histological inflammation in human arterial tissue.
Ideal Study Design
A prospective RCT of 50 patients undergoing carotid endarterectomy, with preoperative 18F-FDG PET-CT TBR measurement and postoperative histological analysis of plaque macrophage density (CD68+ cells), to determine correlation between TBR and tissue inflammation.
Limitation: Invasive and ethically limited; cannot be generalized to all vascular beds.
Prospective Cohort StudyLevel 2bPrognostic value of 18F-FDG PET-CT TBR for predicting future cardiovascular events.
Prognostic value of 18F-FDG PET-CT TBR for predicting future cardiovascular events.
What This Would Prove
Prognostic value of 18F-FDG PET-CT TBR for predicting future cardiovascular events.
Ideal Study Design
A prospective cohort of 1000+ adults with subclinical atherosclerosis, with baseline 18F-FDG PET-CT TBR measurement and 5-year follow-up for major adverse cardiovascular events (MACE), adjusting for traditional risk factors.
Limitation: Cannot prove TBR is a causal mediator — only a predictor.
Cross-Sectional StudyLevel 3Association between 18F-FDG PET-CT TBR and other biomarkers of inflammation (e.g., CRP, IL-6) in the same individuals.
Association between 18F-FDG PET-CT TBR and other biomarkers of inflammation (e.g., CRP, IL-6) in the same individuals.
What This Would Prove
Association between 18F-FDG PET-CT TBR and other biomarkers of inflammation (e.g., CRP, IL-6) in the same individuals.
Ideal Study Design
A cross-sectional study of 200 adults with atherosclerosis, measuring 18F-FDG PET-CT TBR and plasma inflammatory biomarkers (CRP, IL-6, TNF-α) simultaneously to assess correlation.
Limitation: Cannot establish temporal sequence or causality.
Evidence from Studies
Supporting (1)
Effect of statins on arterial wall inflammation as assessed by 18F-FDG PET CT: an updated systematic review and meta-analysis
This study found that when people take statins, their artery inflammation goes down — and this can be seen clearly with a special scan called 18F-FDG PET-CT. So yes, the scan works well to measure inflammation without needing surgery.